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Abstract 
Nanoemulsion (NE) is defined as an O/W or W/O emulsion producing a 
transparent product that has a droplet size from 20-200nm and does not 
have the tendency to coalesce. It is promising for transdermal delivery of 
drugs as an efficient route of drug administration. Several mechanisms 
have been proposed to explain the advantages of nanoemulsions for the 
transdermal delivery of drugs. In transdermal delivery, the goal of 
dosage design is to maximize the flux through the skin into systemic 
circulation. A useful strategy for improving percutaneous flux is to 
improve the concentration of drug or choose an appropriate vehicle for 
the transdermal delivery. The nanoemulsions system should be a 
promising vehicle due to powerful ability to deliver drug through skins. 
With these approaches, the aim of this present study is to review the 
potential of nanoemulsion formulation for transdermal delivery of pure 
phytopharmaceuticals and poorly soluble drugs. Some nanoemulsions 
have however exhibited sufficiently high level of stability for them to be 
proposed as vehicle for drug delivery. Using the transdermal route 
eliminates the side effects, increases patient compliance, avoids first-
pass metabolism, enhance bioavailability and maintains the plasma drug 
level for a longer period of time. 
Key words: Transdernmal, poorly soluble drug, phytopharmaceuticals, 
nanoemulsion. 
Introduction 
The confusion as to what differentiates a 
microemulsion [1] and an emulsion has been 
further complicated by the emergence in the 
literature of another oil and water dispersion, 
known as a nanoemulsion, although the terms 
mini or sub micron emulsion have also been used. 
The distinction between a microemulsion and a 
nanoemulsion is even blurred because the 
description of a nanoemulsion is very similar to 
that of a microemulsion in that they are both oil-
in-water dispersion of small droplet diameter (for 
nanoemulsion a range of 20-200nm [1, 2] is 
typically quoted) and of narrow droplet size 
distribution. Although the physical appearance of 
a nanoemulsion resembles that of a 
microemulsion, in that both systems are 
transparent (or translucent) and of low viscosity, 
there is an essential difference between the two 
systems, namely that a nanoemulsion (i.e. an 
emulsion) is, as at best, kinetically stable, while 
microemulsion is thermodynamically stable [3]. 
As a consequence, many of the nanoemulsion 
reported in the literature do not posses long term 
stability. Some nanoemulsions have however 
exhibited sufficiently high level of stability for 
them to be proposed as vehicle for drug delivery 
[4]. It is worth commenting that, while the 
distinction between a nanoemulsion and 
emulsion, in terms of their size, rather arbitrary, 
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nanoemulsion because of their small droplet size, 
posses a higher stability against sedimentation or 
creaming that an emulsion [5, 6]. 
 
One supposed advantage of a nanoemulsion over 
a microemulsion is that it requires a lower 
surfactant concentration for its formation. For 
example, nanoemulsion droplets of radius 60-70 
nm and containing 20wt% isohexadecane; were 
using only 4wt% of a mixture polyoxyethylene 4-
dodecyl ether and polyoxyethylene 6-dodecyl 
ether surfactants [7].  
 
When comparing this surfactant concentration 
with the 20wt% surfactant typically needed to 
prepare a microemulsion containing a comparable 
amount of oil, one should realize that the droplet 
size of microemulsion thus produced would 
typically be 10nm. Consequently [8], in order to 
produce nanoemulsion droplet of the comparable 
size, the amount of surfactant required would 
increase (the surfactant of droplet varies with that 
of the squares of the droplet radius) to a 
compatible value. The pertinent question (in 
terms of drug delivery) is what is most beneficial 
or the optimal size of the droplets. Recent results 
suggest that small may not always be better, 
especially because of the need for large amount 
of surfactant which, under certain circumstances, 
actually hinders drug absorption [9]. 
 
Nanoemulsion, as consequences of their relative 
high kinetic stability, low viscosity, and 
transperancy/transluency, are very attractive for 
range of industrial applications, including the 
pharmaceutical field where they have been 
explored as drug delivery systems [9-11]. It is 
worth nothing however that the  most stable 
nanoemulsion are generally, although not 
exclusively, prepared using expensive, high 
energy input method such as microfluidization, 
ultrasonication, which makes their production 
expensive [3,12]. 
 
 
 
 
Objectives: Improving the following 
parameters:- 
• Effectiveness and bioavailability 
• Ease of development  
• Breadth of application  
• Stability  
• Reduce side effect and toxicity  
• Drug loading  
• Uniformity 
• Costs  
• Ease of formulation & manufacture  
• Drug properties  
• Therapeutic considerations 
 
Nanoemulsions, swollen micelles, micelles 
There is much debate in the literature as to what 
exactly differentiates a nanoemulsion from a 
micelle at low volume fractions of disperse 
phase. Some investigators have perceived a 
difference between nanoemulsions and micellar 
systems containing solubilized oil or water, and 
have used the terms “swollen” micellar solution 
or solubilized micellar solutions to describe such 
systems [13]. These investigators argue that the 
term nanoemulsion should be restricted to system 
in which the droplets are the large enough size 
such that the physical properties of the dispersed 
oil or water phase are indistinguishable from 
those of the corresponding oil or water phase, 
thereby theoretically making it possible to 
distinguish between oil-in-water (or water-in-oil) 
nanoemulsion and micellar solutions containing 
small amounts of solubilized oil (water) [14]. 
However, in most cases, the transformation 
between micelles progressively swollen with oil 
(water) and a nanoemulsion containing an 
isotropic core of oil (water) appears to be gradual 
with no obvious transition point. As a 
consequence, there is no simple method available 
for determining the oil (water) content at which 
the core of the swollen micelles becomes 
identical to that of bulk phase. Many researchers 
therefore use the terms nanoemulsion to include 
swollen micelles, but not micelles containing no 
oil (or water). 
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Nanoemulsions and cosolvent systems 
The above broad definition does not require a 
nanoemulsion to contain any microstructure. In 
other words, it includes systems that are co-
solvents, i.e. systems in which the constituent 
components are molecularly dispersed. Most 
researchers in the field agree, however, that for 
nanoemulsion to be formed, it is important that 
the system contains some definite structure. In 
other words, there is definite boundary between 
oil and water phases, and at which the 
amphiphilic molecules are located and that a co-
solvent is not a type of nanoemulsion. The only 
way to distinguish a nanoemulsion from a co-
solvent unambiguously is to perform either 
scattering study (light, X-ray or neutrons) or 
PFG-NMR measurements. Region of co-solvent 
formation generally appear at low concentrations 
of oil or water [14, 15]. 
 
Nanoemulsion as Drug Delivery Systems 
It is clear from its description that nanoemulsion 
posses a number of properties that make their use 
as drug delivery vehicles particularly attractive. 
Indeed, nanoemulsions (or microemulsion) were 
first studied with the view of using them as 
potential vehicles for poorly-water soluble drugs, 
in the mid 1970s by Elworthy and Attwood [16]. 
However, it was not until the mid to late 1980s 
that they were widely investigated as drug 
delivery systems; this interest being largely the 
result of the arrival on the market of the 
cyclosporine A microemulsion pre concentrate, 
Neoral. 
 
Among the physical properties that make 
nanoemulsions attractive as drug delivery 
vehicles is their transparent nature, which means 
that the product is not only aesthetically pleasing, 
but allows easy visualization of any 
contamination. The small size of the domains 
present means that a nanoemulsion can be 
sterilized by terminal filtration. Furthermore, 
depending on the composition of the 
nanoemulsion, it may be possible to heat sterilize 
the nanoemulsions. Since the oil-in-water 
nanoemulsions are able to incorporate lipophilic 
components, they can be used to facilitate the 
administration of water-insoluble drugs [17]. 
Significantly, the small droplet size provides a 
large interfacial area for rapid drug release, and 
so the drug should exhibit an enhanced 
bioavailability, enabling a reduction in dose, 
more consistent temporal profiles of drug 
absorption, and the protection of drugs from the 
hostile environment of the body. In addition to 
increasing the rate of drug release, nanoemulsion 
can also be used as a reservoir and actually slow 
the release of drug and prolong its effect, thereby 
avoiding high concentrations in the blood. 
Whether a drug is rapidly or slowly released from 
nanoemulsion depends very much on the affinity 
of the drug for the nanoemulsion. Since 
nanoemulsions contain surfactants (co-
surfactants) and other excipients, they may serve 
to increase the membrane permeation of drug [18, 
19]. 
 
Drug delivery routes across human skin 
Drug molecules in contact with the skin surface 
can penetrate by three potential pathways: 
through the sweat ducts, via the hair follicles and 
sebaceous glands (collectively called the shunt or 
appendageal route), or directly across the stratum 
corneum (Fig. 1). 
 
The relative importance of the shunt or 
appendageal route versus transport across the 
stratum corneum has been debated by scientists 
over the years [20-22] and is further complicated 
by the lack of a suitable experimental model to 
permit separation of the three pathways. In vitro 
experiments tend to involve the use of hydrated 
skin or epidermal membranes so that appendages 
are closed by the swelling associated with 
hydration. Scheuplein and colleagues [23, 24] 
proposed that a follicular shunt route was 
responsible for the pre steady-state permeation of 
polar molecules and flux of large polar molecules 
or ions that have difficulty diffusing across the 
intact stratum corneum. 
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Fig.1. Simplified representation of skin showing routes of penetration: 1. through the sweat ducts; 2. directly across the stratum 
corneum; 3. via the hair follicles. 
 
Water is an essential component of the stratum 
corneum, which acts as a plasticizer to prevent 
cracking of the stratum corneum and is also 
involved in the generation of natural moisturizing 
factor (NMF), which helps to maintain 
suppleness. Traditionally it was thought that 
hydrophilic chemicals diffuse within the aqueous 
regions near the outer surface of intracellular 
keratin filaments (intracellular or transcellular 
route) whilst lipophilic chemicals diffuse through 
the lipid matrix between the filaments 
(intercellular route) [24] (see Fig. 2).  
 
Fig.2. Diagrammatic representation of the stratum corneum and the intercellular and transcellular routes of penetration. 
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A molecule traversing via the transcellular route 
must partition into and diffuse through the 
keratinocyte, but in order to move to the next 
keratinocyte, the molecule must partition into and 
diffuse through the estimated lipid lamellae 
between each keratinocyte. This series of 
partitioning into and diffusing across multiple 
hydrophilic and hydrophobic domains is 
unfavourable for most drugs. Consequently, 
based on more recent data the intercellular route 
is now considered to be the major pathway for 
permeation of most drugs across the stratum 
corneum [25-29]. Drug permeation across the 
stratum corneum obeys Fick’s first law (equation 
1) where steady-state flux (J) is related to the 
diffusion coefficient (D) of the drug in the 
stratum corneum over a diffusional path length or 
membrane thickness (h), the partition coefficient 
(P) between the stratum corneum and the vehicle, 
and the applied drug concentration (C0) which is 
assumed to be constant:  
 
      ………….  (1) 
 
 
Equation (1) aids in identifying the ideal 
parameters for drug diffusion across the skin. The 
influence of solubility and partition coefficient of 
a drug on diffusion across the stratum corneum 
has been extensively studied and an excellent 
review of the work was published by Katz and 
Poulsen [30]. Molecules showing intermediate 
partition coefficients (log P octanol/water of 1-3) 
have adequate solubility within the lipid domains 
of the stratum corneum to permit diffusion 
through this domain whilst still having sufficient 
hydrophilic nature to allow partitioning into the 
viable tissues of the epidermis [31]. Optimal 
permeability has been shown to be related to low 
molecular size [22] (ideally less than 500 Da 
[32]) as this affects diffusion coefficient, and low 
melting point which is related to solubility. 
 
 
 
Penetration enhancement by stratum corneum 
modification 
There is extensive literature, including many 
excellent reviews [33-36] describing chemicals 
and methods to reduce the barrier capability of 
the stratum corneum in order to promote skin 
penetration. The enhancer activity of many 
classes of chemicals has been tested including 
water, surfactants, essential oils and terpenes, 
alcohols, dimethyl sulfoxide (DMSO), Azone 
analogues. In addition some chemicals have been 
identified as penetration retarders. The activity of 
penetration enhancers may be expressed in terms 
of an enhancement ratio (ER): 
 
 
 
Barry and coworkers [37-39] devised the lipid-
protein partitioning (LPP) theory to describe the 
mechanisms by which enhancer’s effect skin 
permeability: 
• Disruption of the intercellular bilayer lipid 
structure 
• Interaction with the intracellular proteins of 
the stratum corneum 
• Improvement of partitioning of a drug, 
coenhancer, or cosolvent into the       
stratum corneum. 
 
Hydration 
Water is the most widely used and safest method 
to increase skin penetration of both hydrophilic 
[40] and lipophilic permeants [41]. The water 
content of the stratum corneum is around 15 to 
20% of the dry weight but can vary according to 
humidity of the external environment. 
 
Lipid Disruption/Fluidization by Chemical 
Penetration Enhancers 
Many enhancers, such as Azone, DMSO, 
alcohols, fatty acids and terpenes, have been 
shown to increase permeability by disordering or 
‘fluidizing’ the lipid structure of the stratum 
corneum [42, 43].  
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Interaction with Keratin 
In addition to their effect on stratum corneum 
lipids, chemicals such as DMSO, 
decylmethylsulphoxide, urea and surfactants also 
interact with keratin in the corneocytes [44]. 
  
Increased Partitioning and Solubility in 
Stratum Corneum  
A number of solvents (such as ethanol, propylene 
glycol, TranscutolÒ and N-methyl pyrrolidone) 
increase permeant partitioning into and solubility 
within the stratum corneum, hence increasing P 
in Fick’s equation (Eqn. 1). Indeed, ethanol was 
the first penetration enhancer-cosolvent 
incorporated into transdermal systems [45]. 
 
Combined Mechanisms 
Fick’s law (Eqn. 1) shows that a combination of 
enhancement effects on diffusivity (D) and 
partitioning (K) will result in a multiplicative 
effect. Synergistic effects have been 
demonstrated for many combinations, such as 
Azone and propylene glycol [46], Azone and 
Transcutol [47], oleic acid and propylene glycol, 
terpenes and propylene glycol [48], various 
combinations and alcohols e.g. N-
methylpyrrolidone and propylene glycol, urea 
analogues and propylene glycol [49], 
supersaturation and oleic acid [50].  
 
Skin Irritancy and Toxicity Due to Chemical 
Penetration Enhancers 
Chemical penetration enhancers increase skin 
permeability by reversibly damaging or altering 
the physicochemical nature of the stratum 
corneum to reduce its diffusional resistance. One 
of the problems associated with many chemical 
penetration enhancers is that they cause irritancy 
in the skin [51].  
 
Other Physical and Electrical Methods 
These include iontophoresis (driving charged 
molecules into the skin by a small direct current – 
approximately 0.5 mA/cm2), phonophoresis 
(cavitation caused by low frequency ultrasound 
energy increases lipid fluidity), electroporation 
(application of short micro- to milli-second 
electrical pulses of approximately 100-1000 
V/cm to create transient aqueous pores in lipid 
bilayers) and photomechanical waves (laser-
generated stress waves reported to cause a 
possible transient permeabilisation of the stratum 
corneum [52-54]).  
 
An overview of current techniques  
Shinoda K et al reported that the microemulsions 
are thermodynamically stable isotropic system in 
which two immiscible liquids (i.e., water and oil) 
are mixed to form a single phase by means of an 
appropriate surfactant or its mixture. These are 
homogeneous systems of low viscosity that can 
be prepared over wide range of surfactant 
concentrations and oil-to-water ratios. Hoar and 
Schulman introduced the word microemulsion 
(ME), which they defined as a transparent 
obtained by titrating a normal coarse emulsion 
with medium-chain alcohols1.The short to 
medium chain alcohols are generally considered 
as co surfactant in the ME system. 
 
Kriwet K et al studied that the nanoemulsions 
have improved transdermal permeation of many 
drugs over the conventional topical formulations 
such as emulsions and gels.   This  article  
describes  the  potential  of  nanoemulsion 
systems  in  transdermal  delivery  of  aceclofenac  
using nonirritating, pharmaceutically acceptable 
ingredients without using additional permeation 
enhancers, because excipients of nanoemulsions 
themselves act as permeation enhancers. 
 
Faiyaz et al reported that the aim of the present 
study was to investigate the potential of a 
nanoemulsion formulation for transdermal 
delivery of aceclofenac. Various oil-in-water 
nanoemulsions were pre- pared by the 
spontaneous emulsification method. The nano- 
emulsion area was identified by constructing 
pseudo ternary phase diagrams. The prepared 
nanoemulsions were subjected to different 
thermodynamic stability tests. The nanoemulsion 
formulations that passed thermodynamic stability 
tests were characterized for viscosity, droplet 
size, transmission electron microscopy, and 
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refractive index. Transdermal permeation of 
aceclofenac through rat abdominal skin was 
determined by Franz diffusion cell. The in vitro 
skin permeation profile of optimized formulations 
was compared with that of aceclofenac 
conventional gel and nanoemulsion gel.   
 
Benson et al reported the transdermal drug 
delivery: penetration enhancement techniques. 
Transdermal delivery of drugs through the skin to 
the systemic circulation provides a convenient 
route of administration for a variety of clinical 
indications. Transdermal delivery systems are 
currently available containing scopolamine 
(hyoscine) for motion sickness, clonidine and 
nitroglycerin for cardiovascular disease, fentanyl 
for chronic pain, nicotine to aid smoking 
cessation, etc. 
 
Wu H et al  investigated that the A variety of 
water-in-oil nanoemulsions were prepared using 
sorbitan monooleate (Span®80), polyoxyethylene 
20 sorbitan monooleate (Tween®80), olive oil 
and water. The nanoemulsions were tested for 
their ability to facilitate transport of a model 
hydrophilic solute, inulin, across hairless and 
hairy mouse skin and hairy rat skin following 
topical in vitro application. The transport of 
inulin incorporated in water-in-oil nanoemulsions 
was found to be significantly higher (5- to 15-
fold) than that obtained with micellar dispersions 
or aqueous controls. The rate and extent of inulin 
transport across hairy mouse skin was found to be 
highly dependent on the hydrophile–lipophile 
balance (HLB) of the surfactant mixture in the 
nanoemulsion. 
 
Xu J. et al investigated that the  preparation of 
neem oil microemulsion and its acaricidal activity 
in vitro was developed in this study. In these 
systems, the mixture of Tween-80 and the sodium 
dodecyl benzene sulfonate (SDBS) (4:1, by 
weight) was used as compound surfactant; the 
mixture of compound surfactant and hexyl 
alcohol (4:1, by weight) was used as emulsifier 
system; the mixture of neem oil, emulsifier 
system and water (1:3.5:5.5, by weight) was used 
as neem oil microemulsion. All the mixtures were 
stired in 800 rpm for 15min at 40 8C. The 
acaricidal activity was measured by the speed of 
kill. The whole lethal time value of 10% neem oil 
microemulsion was 192.50 min against Sarcoptes 
scabiei var. cuniculi larvae in vitro. 
 
Mei Z et al investigated that the Triptolide (TP) 
has been shown to have anti-inflammatory, 
immunosuppressive, anti-fertility and 
antineoplastic activities. However, its clinical use 
is restricted to some content due to its poor water 
solubility and some toxic effects. In order to find 
innovative ways for administering TP and 
alleviating its disadvantages, the controlled 
release delivery systems such as solid lipid 
nanoparticle (SLN) and microemulsion have been 
developed. In the present paper we describe the 
preparation and some characterization of 
specialized delivery systems for TP. The 
transdermal delivery capacity and anti-
inflammatory activity were also evaluated. The 
results indicated that these SLN dispersions and 
microemulsions could serve as efficient 
promoters for the TP penetrating into skin. 
 
Teichmann A et al investigated that the 
Comparison of stratum corneum penetration and 
localization of a lipophilic model drug applied in 
an o/w microemulsion and an amphiphilic cream. 
In the present study, the lipophilic dye curcumin 
incorporated in an oil-in-water microemulsion 
and in an amphiphilic cream was applied onto the 
skin of human volunteers. 
 
Cui J et al reported that the Curcumin is a poorly 
water-soluble drug and its oral bioavailability is 
very low. A new selfmicroemulsifying drug 
delivery system (SMEDDS) has been 
successfully developed to improve the solubility 
and oral absorption of curcumin. Suitable 
compositions of SMEDDS formulation were 
screened via solubility studies of curcumin and 
compatibility tests. The formulation of curcumin-
loaded SMEDDS was optimized by a simplex 
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lattice experiment design. The optimal 
formulation of SMEDDS was comprised of 
57.5% surfactant (emulsifier OP: Cremorphor EL 
= 1:1), 30.0% co-surfactant (PEG 400) and 
12.5% oil (ethyl oleate). 
 
Tsai Y et al investigated that the hesperetin is one 
of the flavonoids and possess anti-inflammatory, 
UV- protecting and antioxidant effects. 
Permeation issues for topical delivery systems of 
such effects are occasionally problematic, and in 
view of the fact that microemulsions are potential 
carriers for transdermal delivery system, the 
objective of this study was to design an optimal 
microemulsion formulation by in vitro 
permeation study for hesperetin topical dosage 
form and determine its topical photoprotective 
effect and skin irritation by in vivo study. The 
hesperetin-loaded microemulsion showed an 
enhanced in vitro permeation compared to the 
aqueous and isopropyl myristate (IPM) 
suspension dosage form of hesperetin. 
 
Lin C et al reported that the ternary phase 
diagram of a curcumin-encapsulated O/W 
microemulsion system using food-acceptable 
components, lecithin and Tween 80 as the 
surfactants and ethyl oleate as the oil phase, was 
constructed. The stability and characterisation of 
curcumin in microemulsion were investigated. 
The results indicated that a composition of 
curcumin microemulsion (DI water: surfactants 
(the mole ratio of lecithin/Tween 80 was 0.3): EO 
= 10:1.7:0.4 in wt ratio) was stable for 2 months 
with an average diameter of 71.8 ± 2.45 nm, as 
detected by UV–Vis spectra and diameter 
distributions. The microemulsion possesses an 
ability to be diluted with aqueous buffer without 
destroying its structure for 48 h. 
 
Conclusion 
Recent review focused on the development of 
nanoemulsions, which seem to be an interesting 
alternative for transdermal drug delivery. The 
nanoemulsions system should be a promising 
vehicle due to powerful ability to deliver drug 
through skins. With these approaches, the aim of 
this present study is to review the potential of 
nanoemulsion formulation for transdermal 
delivery of pure phytopharmaceuticals and poorly 
soluble drugs.  
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